• Explore /
  • Poster
  • / Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.

Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.

Abstract Video & Slides Poster

Authors

Saad Usmani

Saad Zafar Usmani

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Saad Zafar Usmani , Thomas G. Martin , Jesus G. Berdeja , Andrzej J. Jakubowiak , Mounzer E. Agha , Adam D. Cohen , Abhinav Deol , Myo Htut , Alexander M. Lesokhin , Nikhil C. Munshi , Elizabeth O'Donnell , Carolyn Chang Jackson , Tzu-min Yeh , Arnob Banerjee , Enrique Zudaire , Deepu Madduri , Changwei Zhou , Lida Bubuteishvili-Pacaud , Yi Lin , Sundar Jagannath

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03548207

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8028)

DOI

10.1200/JCO.2022.40.16_suppl.8028

Abstract #

8028

Poster Bd #

452

Abstract Disclosures

Similar Posters

First Author: Yi Lin

First Author: Karnav Modi

Poster

2021 ASCO Annual Meeting

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

First Author: Luciano J. Costa

First Author: Nizar J. Bahlis